Incyte Corp.

-1.17 (-1.55%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)16.38B
Current PE30.65
Forward PE 29.79
2yr Forward PE 21.31
See more stats
Estimates Current Quarter
Revenue$813.43 Million
Adjusted EPS$0.58
See more estimates
10-Day MA$74.43
50-Day MA$70.36
200-Day MA$75.21
See more pivots

Incyte Corp. Stock, NASDAQ:INCY

1801 Augustine Cut-Off, 1801 Augustine Cut-Off, Wilmington, Delaware 19803
United States of America
Phone: +1.302.498.6700
Number of Employees: 1773


Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.